Bone marrow-sparing intensity-modulated radiation therapy for Stage I seminoma

References

• de Wit R, Fizazi K. Controversies in the management of clinical stage I testis cancer. J Clin Oncol 2006;24: 5482–92.
   PubMed Web of Science ®Google Scholar
• Fossa SD, Horwich A, Russell JM, Roberts JT, Cullen MH, Hodson NJ, . Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J Clin Oncol 1999;17:1146.
   PubMed Web of Science ®Google Scholar
• Jones WG, Fossa SD, Mead GM, Roberts JT, Sokal M, Horwich A, . Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: A report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol 2005;23:1200–8.
   PubMed Web of Science ®Google Scholar
• Aass N, Fossa SD, Host H. Acute and subacute side effects due to infra-diaphragmatic radiotherapy for testicular cancer: A prospective study. Int J Radiat Oncol Biol Phys 1992;22:1057–64.
   PubMed Web of Science ®Google Scholar
• Coia LR, Hanks GE. Complications from large field intermediate dose infradiaphragmatic radiation: An analysis of the patterns of care outcome studies for Hodgkin's disease and seminoma. Int J Radiat Oncol Biol Phys 1988;15:29–35.
   PubMed Web of Science ®Google Scholar
• Fossa SD, Aass N, Kaalhus O. Radiotherapy for testicular seminoma stage I: Treatment results and long-term post-irradiation morbidity in 365 patients. Int J Radiat Oncol Biol Phys 1989;16:383–8.
   PubMed Web of Science ®Google Scholar
• Hamilton CR, Horwich A, Bliss JM, Peckham MJ. Gastrointestinal morbidity of adjuvant radiotherapy in stage I malignant teratoma of the testis. Radiother Oncol 1987;10: 85–90.
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Schmoll HJ. Secondary neoplasms following treatment of malignant germ cell tumors. J Clin Oncol 1993;11:1703–9.
   PubMed Web of Science ®Google Scholar
• Fossa SD, Langmark F, Aass N, Andersen A, Lothe R, Borresen AL. Second non-germ cell malignancies after radiotherapy of testicular cancer with or without chemotherapy. Br J Cancer 1990;61:639–43.
   PubMed Web of Science ®Google Scholar
• Travis LB, Curtis RE, Storm H, Hall P, Holowaty E, Van Leeuwen FE, . Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 1997;89:1429–39.
   PubMed Web of Science ®Google Scholar
• van Leeuwen FE, Stiggelbout AM, van den Belt-Dusebout AW, Noyon R, Eliel MR, van Kerkhoff EH, . Second cancer risk following testicular cancer: A follow-up study of 1,909 patients. J Clin Oncol 1993;11:415–24.
   PubMed Web of Science ®Google Scholar
• Travis LB, Andersson M, Gospodarowicz M, Van Leeuwen FE, Bergfeldt K, Lynch CF, . Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst 2000;92:1165–71.
   PubMed Web of Science ®Google Scholar
• Zwahlen DR, Martin JM, Millar JL, Schneider U. Effect of radiotherapy volume and dose on secondary cancer risk in stage I testicular seminoma. Int J Radiat Oncol Biol Phys 2008;70:853–8.
   PubMed Web of Science ®Google Scholar
• Majewski W, Majewski S, Maciejewski A, Kolosza Z, Tarnawski R. Adverse effects after radiotherapy for early stage (I,IIa,IIb) seminoma. Radiother Oncol 2005;76:257–63.
   PubMed Web of Science ®Google Scholar
• Schairer C, Hisada M, Chen BE, Brown LM, Howard R, Fossa SD, . Comparative mortality for 621 second cancers in 29356 testicular cancer survivors and 12420 matched first cancers. J Natl Cancer Inst 2007;99:1248–56.
   PubMedGoogle Scholar
• Zagars GK, Ballo MT, Lee AK, Strom SS. Mortality after cure of testicular seminoma. J Clin Oncol 2004;22:640–7.
   PubMed Web of Science ®Google Scholar
• Warde P, Specht L, Horwich A, Oliver T, Panzarella T, Gospodarowicz M, . Prognostic factors for relapse in stage I seminoma managed by surveillance: A pooled analysis. J Clin Oncol 2002;20:4448–52.
   PubMed Web of Science ®Google Scholar
• Martinez-Monge R, Fernandes PS, Gupta N, Gahbauer R. Cross-sectional nodal atlas: A tool for the definition of clinical target volumes in three-dimensional radiation therapy planning. Radiology 1999;211:815–28.
   PubMed Web of Science ®Google Scholar
• Martin JM, Joon DL, Ng N, Grace M, Gelderen DV, Lawlor M, . Towards individualised radiotherapy for Stage I seminoma. Radiother Oncol 2005;76:251–6.
   PubMed Web of Science ®Google Scholar
• Ahmed RS, Kim RY, Duan J, Meleth S, De Los Santos JF, Fiveash JB. IMRT dose escalation for positive para-aortic lymph nodes in patients with locally advanced cervical cancer while reducing dose to bone marrow and other organs at risk. Int J Radiat Oncol Biol Phys 2004;60:505–12.
   PubMed Web of Science ®Google Scholar
• Argiris A, Maris T, Vlahos L. T2 relaxation times of irradiated vertebral bone marrow in patients with seminoma. Magn Reson Imaging 1997;15:335–40.
   PubMed Web of Science ®Google Scholar
• Hayman JA, Callahan JW, Herschtal A, Everitt S, Binns DS, Hicks RJ, . Distribution of proliferating bone marrow in adult cancer patients determined using FLT-PET imaging. Int J Radiat Oncol Biol Phys 2010.
   Web of Science ®Google Scholar
• Chavaudra J, Bridier A. [Definition of volumes in external radiotherapy: ICRU reports 50 and 62]. Cancer Radiother 2001;5:472–8.
   PubMedGoogle Scholar
• Hamilton C, Horwich A, Easton D, Peckham MJ. Radiotherapy for stage I seminoma testis: Results of treatment and complications. Radiother Oncol 1986;6:115–20.
   PubMed Web of Science ®Google Scholar
• Travis LB, Fossa SD, Schonfeld SJ, McMaster ML, Lynch CF, Storm H, . Second cancers among 40,576 testicular cancer patients: Focus on long-term survivors. J Natl Cancer Inst 2005;97:1354–65.
   PubMed Web of Science ®Google Scholar
• Boice JD, Jr., Engholm G, Kleinerman RA, Blettner M, Stovall M, Lisco H, . Radiation dose and second cancer risk in patients treated for cancer of the cervix. Radiat Res 1988;116:3–55.
   PubMed Web of Science ®Google Scholar
• Inskip PD, Stovall M, Flannery JT. Lung cancer risk and radiation dose among women treated for breast cancer. J Natl Cancer Inst 1994;86:983–8.
   PubMedGoogle Scholar
• Travis LB, Hill D, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, . Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 2005;97:1428–37.
   PubMed Web of Science ®Google Scholar
• Albuquerque K, Giangreco D, Morrison C, Siddiqui M, Sinacore J, Potkul R, . Radiation-related predictors of hematologic toxicity after concurrent chemoradiation for cervical cancer and implications for bone marrow-sparing pelvic IMRT. Int J Radiat Oncol Biol Phys 2010.
   PubMed Web of Science ®Google Scholar
• Mell LK, Tiryaki H, Ahn KH, Mundt AJ, Roeske JC, Aydogan B. Dosimetric comparison of bone marrow-sparing intensity-modulated radiotherapy versus conventional techniques for treatment of cervical cancer. Int J Radiat Oncol Biol Phys 2008;71:1504–10.
   PubMed Web of Science ®Google Scholar
• Hall EJ, Wuu CS. Radiation-induced second cancers: The impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 2003;56:83–8.
   PubMed Web of Science ®Google Scholar
• Cozzi L, Dinshaw KA, Shrivastava SK, Mahantshetty U, Engineer R, Deshpande DD, . A treatment planning study comparing volumetric arc modulation with RapidArc and fixed field IMRT for cervix uteri radiotherapy. Radiother Oncol 2008;89:180–91.
   PubMed Web of Science ®Google Scholar
• Shaffer R, Morris WJ, Moiseenko V, Welsh M, Crumley C, Nakano S, . Volumetric modulated Arc therapy and conventional intensity-modulated radiotherapy for simultaneous maximal intraprostatic boost: A planning comparison study. Clin Oncol (R Coll Radiol) 2009; 21:401–7.
   PubMed Web of Science ®Google Scholar
• Bieri S, Rouzaud M, Miralbell R. Seminoma of the testis: Is scrotal shielding necessary when radiotherapy is limited to the para-aortic nodes? Radiother Oncol 1999;50:349–53.
   PubMed Web of Science ®Google Scholar
• Howell RM, Hertel NE, Wang Z, Hutchinson J, Fullerton GD. Calculation of effective dose from measurements of secondary neutron spectra and scattered photon dose from dynamic MLC IMRT for 6 MV, 15 MV, and 18 MV beam energies. Med Phys 2006;33:360–8.
   PubMed Web of Science ®Google Scholar
• Joos H, Sedlmayer F, Gomahr A, Rahim HB, Frick J, Kogelnik HD, . Endocrine profiles after radiotherapy in stage I seminoma: Impact of two different radiation treatment modalities. Radiother Oncol 1997;43:159–62.
   PubMed Web of Science ®Google Scholar